FTC: authorized generics benefit consumers, but sometimes used as threat to competitors
This article was originally published in Scrip
Executive Summary
When pharmaceutical companies introduce so-called authorized generics (AGs) – drugs approved as brand-name medicines but marketed by innovator firms as generic equivalents at a lower cost – that practice ultimately reduces prices, benefiting consumers, the Federal Trade Commission (FTC) said in a 31 August report.